Johnson & Johnson $JNJ Shares Sold by Berger Financial Group Inc

Berger Financial Group Inc lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% in the second quarter, HoldingsChannel reports. The fund owned 49,873 shares of the company’s stock after selling 112 shares during the quarter. Berger Financial Group Inc’s holdings in Johnson & Johnson were worth $7,618,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 0.5% in the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after acquiring an additional 1,170,120 shares during the last quarter. Northern Trust Corp raised its stake in shares of Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after acquiring an additional 130,645 shares during the period. Bank of New York Mellon Corp boosted its position in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after purchasing an additional 712,181 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Johnson & Johnson by 2.5% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock worth $3,031,955,000 after acquiring an additional 448,666 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Bank of America lifted their price target on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research note on Friday. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Johnson & Johnson in a report on Saturday, September 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.12.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.2%

Johnson & Johnson stock opened at $188.23 on Tuesday. The firm has a market capitalization of $453.32 billion, a P/E ratio of 20.13, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a 50-day simple moving average of $176.62 and a 200-day simple moving average of $163.00. Johnson & Johnson has a one year low of $140.68 and a one year high of $189.92. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. Johnson & Johnson’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.